Procyrion Named to Becker's List of Disruptive Healthcare Companies to Watch in 2017

Becker's Hospital Review
Founded in 2005, this Houston-based biotechnology company developed the Aortix system. The Aortix, a minimally invasive catheter-based heart pump, is designed to rest the heart by reducing afterload and improve blood flow to vital organs, according to Procyrion. The company said the Aortix is different from other circulatory assist devices, including ventricular assist devices, that involve invasive, high-risk surgical procedures, because it is small enough — 6 millimeters wide and less than 6.5 centimeters long — to allow for deployment without surgery and with minimal procedure risk. Procyrion is a development-stage company, and the Aortix micro-pump is currently in pre-clinical testing to support a first-in-human trial scheduled for the first quarter of 2017.
Read More